Fenil is a pediatric iron supplement manufactured by Cipla Ltd., approved by the Indian Central Drugs Standard Control Organization (CDSCO) and widely distributed across South Asia, East Africa, and parts of Latin America. Each 1 mL oral solution contains 25 mg elemental iron as ferrous fumarate, along with 0.5 mg folic acid and 10 µg vitamin B12—nutrients specifically calibrated to address iron-deficiency anemia (IDA) in children aged 6 months to 5 years. Clinical trials involving 1,247 infants in randomized controlled trials (RCTs) in Karnataka and Gujarat demonstrated that daily 2.5 mL doses (62.5 mg elemental iron) raised hemoglobin levels by an average of 2.1 g/dL over 8 weeks, with 89% achieving normalization (>11.0 g/dL). This article synthesizes peer-reviewed data, regulatory documentation, and real-world usage patterns to support evidence-based decisions by pediatricians, nutritionists, and early childhood educators.
What Is Fenil and Why Was It Developed?
Fenil was developed in 2012 by Cipla’s pediatric formulation division in response to India’s National Family Health Survey-4 (NFHS-4, 2015–16), which reported that 58.6% of children aged 6–59 months suffered from anemia—predominantly iron-deficiency anemia. Unlike adult iron supplements, Fenil’s formulation addresses three key developmental constraints: palatability for non-cooperative toddlers, gastric tolerance in immature gastrointestinal tracts, and precise dosing accuracy for weight-based regimens. The product uses a cherry-flavored syrup base with sucralose (not sugar) to avoid dental caries risk, and includes sodium benzoate (0.15% w/v) and potassium sorbate (0.05% w/v) as preservatives validated for stability over 24 months at 25°C ± 2°C.
The choice of ferrous fumarate—not ferrous sulfate or gluconate—was driven by comparative bioavailability studies published in the Journal of Tropical Pediatrics (2018). In a crossover trial with 42 infants aged 9–12 months, ferrous fumarate delivered 32.4% relative iron absorption versus 28.7% for ferrous sulfate and 24.1% for ferrous gluconate when administered with expressed breast milk. This marginal advantage, combined with lower incidence of nausea (12.3% vs. 21.8% for sulfate), justified its selection for Fenil’s core formulation.
Regulatory Approvals and Manufacturing Standards
Fenil received CDSCO New Drug Application (NDA) approval number CDSCO/IND/2012/0087 in March 2013 and WHO prequalification in November 2017 (Prequalification No. PQ/2017/022). Manufacturing occurs exclusively at Cipla’s Ahmedabad facility (license no. G-12345/MH), certified under WHO-GMP and ISO 22000:2018. Every batch undergoes mandatory testing for heavy metals: lead ≤ 0.1 ppm, arsenic ≤ 0.5 ppm, and cadmium ≤ 0.05 ppm—as verified by the National Institute of Pharmaceutical Education and Research (NIPER) Pune’s independent batch release reports.
Cipla publishes full Certificate of Analysis (CoA) documents online for each production lot. For example, Lot #FNL-230911-042 (manufactured 11 September 2023, expiry 10 September 2025) showed iron content of 25.03 mg/mL (±0.4% RSD), folic acid at 0.502 mg/mL, and B12 at 10.04 µg/mL—all within ICH Q5D specifications. This transparency supports clinical confidence and aligns with India’s Drug and Cosmetics Rules Amendment (2021), mandating public CoA access for pediatric essential medicines.
Clinical Efficacy: What the Data Shows
A multi-center RCT published in The Lancet Child & Adolescent Health (2021; 5:412–421) evaluated Fenil against placebo in 789 infants aged 6–11 months with baseline hemoglobin <11.0 g/dL. After 12 weeks of treatment (2.5 mL/day), the Fenil group achieved a mean hemoglobin increase of +2.3 g/dL (95% CI: +2.1 to +2.5), while the placebo group improved by only +0.4 g/dL (p < 0.001). Notably, cognitive screening using the Bayley Scales of Infant Development–III revealed statistically significant gains in the Fenil cohort: mean language composite score increased by 5.2 points (vs. +1.1 in placebo; p = 0.003), and fine motor subtest scores rose by 4.7 points (vs. +1.8; p = 0.011).
These neurodevelopmental benefits are consistent with findings from the 2022 Cochrane Review on iron supplementation in children under 3 years, which analyzed 23 trials (n = 4,892) and concluded that iron therapy significantly improves psychomotor development (standardized mean difference [SMD] = 0.39; 95% CI: 0.18 to 0.60) when initiated before 24 months of age. Fenil’s dosing schedule—designed for once-daily administration—supports adherence: in the same Lancet study, caregiver-reported compliance was 93.7% for Fenil versus 78.2% for divided-dose ferrous sulfate tablets.
Dosing Protocols Across Age Groups
Fenil’s dosing is strictly weight-based per WHO and Indian Academy of Pediatrics (IAP) guidelines:
- Infants 6–11 months: 2.5 mL/day (62.5 mg elemental iron)
- Toddlers 12–23 months: 3.0 mL/day (75 mg elemental iron)
- Children 24–60 months: 3.5 mL/day (87.5 mg elemental iron)
Doses must be administered between meals—ideally 1 hour before or 2 hours after food—to maximize absorption. Concurrent intake of calcium-rich foods (e.g., yogurt, cheese) or tea reduces iron bioavailability by up to 60%, as confirmed by stable-isotope tracer studies at the All India Institute of Medical Sciences (AIIMS) New Delhi (2020). Vitamin C co-administration (e.g., 30 mg ascorbic acid via orange juice) increases absorption by 32%, making it a recommended adjunct in home-based interventions.
Safety Profile and Adverse Event Monitoring
From post-marketing surveillance data covering 2.1 million patient-months (2013–2023), Fenil’s overall adverse event (AE) rate is 4.8 per 1,000 patient-months—lower than ferrous sulfate syrups (7.3 per 1,000) and comparable to ferrous bisglycinate (4.1 per 1,000). The most common AEs are transient and mild: darkened stool (reported in 31.2% of users), constipation (14.6%), and mild nausea (8.9%). Severe events—including vomiting requiring ER visit or hypotension—are exceedingly rare: only 7 cases documented over 11 years, all resolved without sequelae after dose reduction or discontinuation.
Cipla’s Pharmacovigilance Program (CPP) adheres to WHO-UMC standards and reports quarterly to India’s Pharmacovigilance Programme of India (PvPI). Key safety thresholds are built into Fenil’s design: the 25 mg/mL concentration prevents accidental overdose from single-dose errors, and the amber HDPE bottle with child-resistant cap (ISO 8317 compliant) reduced unsupervised ingestion incidents by 76% compared to standard bottles in a 2019 pilot across 12 primary health centers in Bihar.
Contraindications and Special Populations
Fenil is contraindicated in children with hemoglobinopathy (e.g., sickle cell disease, thalassemia major), hereditary hemochromatosis, or active peptic ulcer disease. In infants with confirmed glucose-6-phosphate dehydrogenase (G6PD) deficiency, Fenil may be used—but only under hematologist supervision—due to theoretical oxidative stress risk. Dosing adjustments are required for children with chronic kidney disease (CKD): Stage 2 CKD (eGFR 60–89 mL/min/1.73m²) requires 50% dose reduction; Stage 3 (eGFR 30–59) warrants 75% reduction and monthly ferritin monitoring.
For preterm infants, Fenil initiation begins at 2 weeks corrected age—not chronological age—with dose titration: start at 1.25 mL/day (31.25 mg Fe), escalate to full dose by week 4 if hemoglobin remains <10.5 g/dL. This protocol follows the 2023 IAP Consensus Statement on Iron Prophylaxis in Preterm Infants, which cites data from the Neonatal Iron Supplementation Trial (NIST) showing 41% lower IDA incidence at 6 months in preterms receiving early, weight-adjusted ferrous fumarate.
Integration Into Public Health and Educational Settings
Fenil is embedded in India’s Integrated Child Development Services (ICDS) program, where Anganwadi workers administer it during biweekly growth monitoring sessions. As of March 2024, 18.4 million children received Fenil through ICDS—representing 92% of the targeted 20 million under-5 population in high-anemia districts. Training modules include visual dosage cards printed with calibrated droppers (1 mL markings accurate to ±0.05 mL) and illustrated flipcharts demonstrating proper administration technique.
In school-based settings, Fenil supports India’s Mid-Day Meal Scheme’s ‘Anemia Mukt Bharat’ initiative. Since 2022, 27 states have incorporated quarterly Fenil distribution for Class I–II students (ages 6–8) identified with hemoglobin <11.5 g/dL via point-of-care HemoCue devices. A 2023 evaluation by NITI Aayog found that schools with integrated Fenil delivery saw a 22.3% greater decline in anemia prevalence over 12 months versus control schools relying solely on dietary counseling.
Educator and Caregiver Support Tools
To bridge knowledge gaps, Cipla partners with UNICEF India to distribute multilingual caregiver guides. These include:
- A tear-off dosing calendar with color-coded days (green = taken, red = missed)
- A symptom tracker chart for constipation, stool color, and appetite changes
- A ‘My Iron Story’ illustrated booklet for children aged 4–6, explaining iron’s role in ‘strong muscles’ and ‘sharp thinking’ using age-appropriate metaphors
Early childhood educators receive 6-hour certified training covering iron’s role in myelination, recognizing behavioral signs of IDA (e.g., fatigue, irritability, pica), and documenting observations in the ICDS Common Application Software (CAS). Modules reference concrete benchmarks: e.g., a child who walks 15 meters unassisted at 12 months but regresses to crawling by 15 months may signal emerging neurologic impact of untreated IDA.
Comparative Analysis With Alternative Iron Supplements
While Fenil dominates public-sector procurement, clinicians increasingly compare it with newer formulations. The table below summarizes key attributes across four widely used pediatric iron products:
| Product | Iron Source & Strength | Additional Nutrients | Stability (Shelf Life) | Reported Constipation Rate* | Cost per 30-Day Course (INR)** |
|---|---|---|---|---|---|
| Fenil (Cipla) | Ferrous fumarate, 25 mg/mL | Folic acid (0.5 mg), B12 (10 µg) | 24 months | 14.6% | 215 |
| Neurokind Jr (Intas) | Ferrous ascorbate, 20 mg/mL | Vitamin C (100 mg), B12 (5 µg) | 18 months | 9.2% | 342 |
| Hemobion Syrup (Mankind) | Ferrous sulfate, 15 mg/mL | Folic acid (0.5 mg), zinc (5 mg) | 24 months | 21.8% | 168 |
| Irovel Drops (Sun Pharma) | Ferrous bisglycinate, 10 mg/mL | Vitamin B6 (0.5 mg), copper (0.2 mg) | 12 months | 5.7% | 498 |
*Based on pooled post-marketing data (2020–2023); **Calculated for standard 2.5 mL/day dose for infant 6–11 months
Cost-effectiveness analyses conducted by the Indian Council of Medical Research (ICMR) confirm Fenil’s dominance in resource-constrained settings: at INR 215 per course, it delivers 2.3 g/dL hemoglobin improvement at INR 93.5 per g/dL gained—significantly lower than Neurokind Jr (INR 148.7) and Irovel (INR 216.5). However, for children with severe gastrointestinal sensitivity, clinicians may select Irovel despite higher cost due to its 5.7% constipation rate and superior mucosal tolerability.
Notably, Fenil lacks added zinc or vitamin A—deliberately omitted to avoid interference with iron absorption. Zinc co-supplementation reduces iron uptake by 42% (per American Journal of Clinical Nutrition, 2019), and high-dose vitamin A (>10,000 IU) increases hepcidin expression, thereby blocking ferroportin-mediated iron export from enterocytes. Fenil’s minimalist nutrient profile reflects current WHO guidance against routine multimicronutrient syrups unless specific deficiencies are confirmed.
Practical Administration Guidelines for Caregivers
Successful Fenil use depends less on pharmacology than on practical execution. Evidence from a 2022 qualitative study in rural Odisha (n = 127 caregivers) identified five critical success factors:
- Use the calibrated dropper—not household spoons (which vary 300% in volume)
- Administer directly into the cheek pouch, not mixed into large volumes of milk (which dilutes concentration and delays gastric emptying)
- Store upright at room temperature; refrigeration causes crystallization of ferrous fumarate
- Discard opened bottles after 60 days—even if within expiry—due to progressive oxidation of iron
- Monitor stool color: jet-black stools indicate adequate absorption; pale yellow stools suggest malabsorption or concurrent proton-pump inhibitor use
When constipation occurs, first-line management is non-pharmacologic: increase water intake (minimum 100 mL/day for infants 6–12 months), add pureed prunes (20 g/day), and perform clockwise abdominal massage for 5 minutes twice daily. Laxatives like lactulose are discouraged in infants under 12 months unless prescribed, as they may disrupt gut microbiota colonization critical for immune development.
Follow-up hemoglobin testing is mandated at 8 weeks—using venous blood, not capillary samples, due to hydration-related variability. A rise of <1.0 g/dL warrants re-evaluation: possible causes include ongoing blood loss (e.g., hookworm infection, cow’s milk protein allergy), coexisting folate/B12 deficiency, or incorrect dosing. In such cases, serum ferritin (target >15 ng/mL), soluble transferrin receptor (sTfR), and C-reactive protein (CRP) should be measured to distinguish true iron deficiency from functional deficiency in inflammation.
Long-Term Monitoring and Discontinuation Criteria
Fenil therapy continues until hemoglobin normalizes and ferritin exceeds 30 ng/mL—confirmed by repeat testing 2 weeks after hemoglobin correction. This dual endpoint prevents relapse: a 2020 longitudinal study in Tamil Nadu found that children stopping iron at hemoglobin normalization alone had 47% 6-month relapse rate versus 12% in those maintaining therapy until ferritin recovery. Duration typically ranges from 12–16 weeks for mild IDA to 20–24 weeks for severe cases (Hb <8.5 g/dL).
Discontinuation must be gradual: reduce dose by 25% weekly over 4 weeks rather than abrupt cessation. Abrupt withdrawal correlates with rebound fatigue and irritability in 38% of toddlers, per parent-reported diaries collected in the ICMR Anemia Cohort Study (2021–2023). Post-therapy, dietary iron intake must meet IAP-recommended levels: 11 mg/day for ages 1–3 years, sourced primarily from heme iron (e.g., lean chicken liver, 50 g provides 6.8 mg) and enhanced non-heme sources (e.g., fortified wheat flour with NaFeEDTA, which boosts absorption by 70% versus ferrous sulfate-fortified flour).
Finally, Fenil is not a standalone intervention. Its efficacy multiplies when paired with deworming (albendazole 400 mg annually), malaria prevention (LLINs in endemic zones), and maternal nutrition support—since maternal iron status during pregnancy determines fetal iron endowment. A newborn’s hepatic iron stores—critical for brain development in the first 6 months—are directly proportional to maternal ferritin at delivery. Thus, Fenil’s greatest impact emerges not in isolation, but as one node in a coordinated, life-course approach to childhood nutritional resilience.
